Clinical Trial Update: Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial update for axitinib in metastatic renal cell cancer has completed; results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Neoplasms
• Renal Cell Carcinoma

Drugs mentioned

• Axitinib (Axitinib)

Snippet

Sponsor: Pfizer | Conditions: Kidney Neoplasms | Phase 3 | Status: COMPLETED | Results posted: 2014-02-04